Add to ORKGABSTRACT. Objective. Apremilast, a specific inhibitor of phosphodiesterase 4, modulates proinflammatory and antiinflammatory cytokine production. A phase IIb randomized, controlled trial (RCT) evaluated the effect of apremilast on patient-reported outcomes (PRO) in psoriatic arthritis (Ps
Psoriasis is an autoimmune disease that affects more than one bodily system with predominantly skin ...
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treat...
<p class="MsoNormal"><span lang="EN-US">Apremilast (AP) is a new phosphodiesterase 4 inhibitor for ...
Copyright © 2015 Peter H. Schafer et al.This is an open access article distributed under theCreative...
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for t...
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammato...
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield D...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, ...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red a...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the...
Phosphodiesterase 4 (PDE4) is a key enzyme in the degradation of cyclic adenosine monophosphate and ...
Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system...
Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administratio...
Psoriasis is an autoimmune disease that affects more than one bodily system with predominantly skin ...
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treat...
<p class="MsoNormal"><span lang="EN-US">Apremilast (AP) is a new phosphodiesterase 4 inhibitor for ...
Copyright © 2015 Peter H. Schafer et al.This is an open access article distributed under theCreative...
Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for t...
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular inflammato...
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield D...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, ...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red a...
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a dysregul...
Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the...
Phosphodiesterase 4 (PDE4) is a key enzyme in the degradation of cyclic adenosine monophosphate and ...
Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system...
Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administratio...
Psoriasis is an autoimmune disease that affects more than one bodily system with predominantly skin ...
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treat...
<p class="MsoNormal"><span lang="EN-US">Apremilast (AP) is a new phosphodiesterase 4 inhibitor for ...